The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma
Open accessAbstract
Vascular endothelial growth factor receptor 1 (VEGFR‐1) is present on endothelial cells and subsets of human tumor cells, raising the hypothesis that angiogenic factors may promote tumor growth both by inducing angiogenesis and directly signaling through activation of VEGFR‐1 on tumor cells. Here, we report that VEGFR‐1 is expressed on a panel of 16 human breast tumor cell lines, and the vasculature and the tumor cell compartment of a subset of breast carcinoma lesions, and that selective signaling through VEGFR‐1 on breast cancer cells supports tumor growth through downstream activation of the p44/42 mitogen‐activated protein kinase (MAPK) or Akt pathways. Ligand‐stimulated proliferation of breast tumor cells was inhibited by specific blockade with an anti‐VEGFR‐1 neutralizing monoclonal antibody. Treatment with anti‐VEGFR‐1 mAb significantly suppressed the growth of DU4475, MCF‐7, BT‐474 and MDA‐MB‐231 breast xenografts in athymic mice. Histological examination of anti‐VEGFR‐1 mAb treated tumor xenografts showed a significant reduction of activation of the p44/42 MAPK or Akt pathways in tumor cells resulting in an increase in tumor cell apoptosis. Importantly, cotreatment with mAbs targeting human VEGFR‐1 on tumor cells and murine VEGFR‐1 on vasculature led to more potent growth inhibition of breast tumor xenografts. The results suggest that VEGF receptors may not only modulate angiogenesis, but also directly influence the growth of VEGF receptor expressing tumors. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Self-citation
Cited by
Shibuya, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423031 · Cited by 1,748
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Self-citationGoel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1520 · Cited by 564
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Metadata
- Authors
- Wu, Y., Hooper, A. T., Zhong, Z., Witte, L., Bohlen, P., Rafii, S., & Hicklin, D. J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-07-18
- Volume
- 119
- Issue
- 7
- Pages
- 1519-1529
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2094912585
- Cited by
- 192
- References
- 3
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma. https://app.cochat.ai/papers/10.1002/ijc.21865
- The paper
- Wu, Y., Hooper, A. T., Zhong, Z., Witte, L., Bohlen, P., Rafii, S., & Hicklin, D. J. (2006). The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.21865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.